Ethyl cyanohydroxyiminoacetate Ethyl cyanohydroxyiminoacetate Ethyl cyanohydroxyiminoacetate (oxyma) is the oxime of ethyl cyanoacetate and finds use as an additive for carbodiimides, such as dicyclohexylcarbodiimide (DCC) in peptide synthesis. It acts as a neutralizing reagent for the basicity or nucleophilicity of the DCC due to its pronounced acidity (pKa 4.60) and suppresses base catalyzed side reactions, in particular racemization. Ethyl cyanohydroxyiminoacetate is obtained in the reaction of ethyl cyanoacetate and nitrous acid (from sodium nitrite and acetic acid) in 87% yield. Because of the rapid hydrolysis of the ester, the reaction should be carried out at pH 4.5, in buffered phosphoric acid the
Di-deuterated linoleic acid ethyl ester Di-deuterated linoleic acid ethyl ester Di-deuterated ethyl linoleate (also known as RT001; Di-deuterated linoleic acid ethyl ester, 11,11-D2-Ethyl Linoleate, Ethyl 11,11-D2-Linoleate) is an experimental, orally-bioavailable synthetic deuterated polyunsaturated fatty acid (PUFA), an isotopologue of an essential omega-6 PUFA, linoleic acid. The deuterated compound, while identical to natural linoleic acid, is resistant to lipid peroxidation which makes studies of its cell-protective properties worthwhile. Investigations of 11,11-D2-Ethyl linoleate (RT001) are being conducted in several neurological indications, including Friedreich’s ataxia and Infantile Neuroaxonal Dystrophy. A double-blind comparator-controlled Phase I/II clinical trial sponsored by Retrotope and Friedreich’s Ataxia Research Alliance was conducted to determine